2010 Report on China Orthopedic Instrument Industry Full Version


2010 Report on China Orthopedic Instrument Industry

PDF USD 1,700
Hard Copy USD 1,600
Enterprise wide USD 2,500

Pages: 59
Tables and Figures:
Published Date: Nov, 2010
Publisher: 168 Research Group
Contact: Mr. Peter Lee 86-10-82965190 86-13161572746 [email protected]


Benefiting from population aging, consumption upgrading and policy support, the orthopedic instrument industry has witnessed rapid development in recent years. The annual compound growth rate during 2006-2009 was as high as 22.1%, and the market size in 2009 reached RMB6 billion. Joint, trauma and vertebral column products, the three major products in Chinese orthopedic instrument market, achieved market size of RMB1.8 billion, RMB1.67 billion and RMB1.49 billion respectively in 2009.

Market Size and Growth Rate, 2006-2009 (RMB bn)

Source: China Orthopaedics;

Subject to R&D and production technology constraints, Chinese orthopedic instrument market is mainly dominated by foreign-funded enterprises (with 56% market share in 2009), including Johnson & Johnson, Medtronic, Synthes, and Stryker. However, by virtue of such advantages as low production cost, mature manufacturing technology, and sound medical marketing channels, local enterprises are scrambling for larger share in the orthopedic instrument market and heading towards the high-end market form low and medium-end market, so, the future will see an evident trend of import products being replaced with domestic products. Trauson Holdings, Kanghui Medical and Weigao Group, the three major domestic enterprises, in particular, held an accumulative total of 17.1% in trauma product market and 13.7% in vertebral column product market in 2009, indicating powerful market competitiveness.

Take Trauson Holdings as an example. In 2009, the company obtained total revenue of RMB211 million, up 21.3% from 2008, hereinto, trauma products realized revenue of RMB135 million and held 8% of the domestic trauma product market, only second to Synthes; vertebral column products made revenue of RMB31 million and occupied 3% of the domestic vertebral column product market, ranking the 6th.

Operating Income and Gross Margin of Trauson Holdings, 2007-2010 (RMB mln)

Source: company annual report;

Trauson Holdings is strengthening production, sales, M&A, and the R&D of new products so as to improve the core competitiveness. In June 2010, the company planned to invest the RMB520 million raised through public offering in capacity expansion and equipment upgrading (about RMB200 million), product R&D, market expansion and marketing channel construction (approximately RMB100 million), and M&A (roughly RMB180 million). Up to June 2010, besides the existing 88 kinds of orthopedic

Never Expires

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

9 + 2 =

Related Listing